Financial Performance - For the fiscal year ending June 30, 2023, the revenue from continuing operations was approximately RMB 58.7 million[7]. - The loss attributable to owners for the fiscal year was approximately RMB 10.8 million, a decrease from a loss of RMB 18.9 million in the previous fiscal year[7]. - The total comprehensive expenses for the fiscal year were approximately RMB 10.1 million, down from RMB 29.3 million in the previous fiscal year[7]. - For the fiscal year 2023, the company recorded revenue from continuing operations of approximately RMB 58,700,000, a significant increase from RMB 6,800,000 in the fiscal year 2022[29]. - The gross profit for fiscal year 2023 was approximately RMB 11,500,000, with a gross profit margin of 19.6%, attributed to satisfactory revenue from ginseng business[30]. - The company incurred a loss of approximately RMB 10,800,000 in fiscal year 2023, compared to a loss of RMB 18,900,000 in fiscal year 2022[36]. - The company reported a pre-tax loss of RMB 9,374,000 for the fiscal year ending June 30, 2023, an improvement from a loss of RMB 20,383,000 in the previous fiscal year[63]. - The total comprehensive loss for the year was RMB 10,073 thousand, down from RMB 29,316 thousand in the previous year, showing a decrease of approximately 66%[200]. Assets and Liabilities - As of June 30, 2023, the company's total assets were approximately RMB 140,600,000 and net liabilities were approximately RMB 316,700,000[37]. - As of June 30, 2023, the group's net current liabilities and net liabilities were approximately RMB 420,273,000 and RMB 316,708,000, respectively[21]. - Current liabilities exceeded current assets by approximately RMB 420,273,000 on June 30, 2023[164]. - The group reported a net debt of approximately RMB 316,708,000 as of June 30, 2023[164]. - As of June 30, 2023, the company's trade and other receivables amounted to RMB 10,399,000[188]. Capital Structure and Financing - As of June 30, 2023, the capital debt ratio was approximately 325.2%, a reduction of 24.0% from 427.9% in the previous year[7]. - The company completed a restructuring agreement on July 28, 2023, issuing 466,000,000 shares at HKD 0.1288 per share, raising approximately HKD 60,000,000[28]. - The company issued 140,000,000 shares at HKD 0.55 per share to creditors, raising approximately HKD 77,000,000 as part of the creditor scheme[28]. - The company issued HKD 120,000,000 in promissory notes to creditors with varying interest rates from 0% to 6% over five years[164]. - The company reported a financing cost of approximately RMB 11,700,000 for fiscal year 2023, a decrease of about 44.9% from RMB 21,200,000 in fiscal year 2022[34]. Ginseng and Forestry Business - The company completed the approved logging volume of approximately 26,953 cubic meters, generating logging revenue of approximately RMB 25.6 million during the fiscal year[12]. - The group's ginseng business generated revenue of approximately RMB 33,100,000 in the fiscal year 2023[15]. - The company has initiated ginseng cultivation in its existing forests, completing the first phase of planting approximately 6 million ginseng plants on 59 acres[14]. - In the fiscal year 2023, the group generated revenue of approximately RMB 25.6 million from forestry management and RMB 33.1 million from ginseng business[83]. Governance and Management - The company has over 18 years of experience in banking, insurance, fund management, and securities management[69]. - The executive team includes individuals with extensive backgrounds in business planning, financial management, and auditing, with over 42 years of experience in accounting and auditing collectively[73][74]. - The company is committed to maintaining high standards of compliance and governance, as evidenced by the qualifications of its board members and executives[74]. - The board consists of ten directors, including two female directors, achieving gender diversity with a target to maintain at least one female director[135]. - The board has adopted a diversity policy, considering various factors such as gender, age, cultural background, and professional experience for board member appointments[134]. Audit and Compliance - The independent auditor's report highlighted significant uncertainty regarding the group's ability to continue as a going concern[21]. - The audit committee acknowledged the independent auditor's report and the potential impact of adjustments on the financial statements[24]. - The Audit Committee, consisting of four independent non-executive directors, oversees the financial reporting process and internal control systems as of June 30, 2023[151]. - The internal control system has been reviewed and deemed effective for the fiscal year 2023, ensuring reasonable assurance against significant misstatements and fraud[160]. Shareholder Communication - The company has implemented measures to ensure effective communication with shareholders and investors[167]. - The company has reviewed its shareholder communication policy and found it to be effective[172]. - The board believes that the group will have sufficient cash resources to meet its operational funding and financial obligations for the next twelve months[165].
中国健康科技集团(01069) - 2023 - 年度财报